JBJ-08-178-01
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer[1][2][3].
Product Specifications
CAS Number
2401867-58-9
UNSPSC
12352005
Target
Proteasome
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jbj-08-178-01.html
Smiles
CC1=CC(NC2=C3C=C(NC(/C=C/CN(C)C)=O)C(OCC)=CC3=NC=C2C#N)=CC=C1OC4=CC5=NC=NN5C=C4
Molecular Formula
C31H30N8O3
Molecular Weight
562.62
References & Citations
[1]Rubin E, et al. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers. Int J Mol Sci. 2024 Jan 15;25 (2) :1064. |[2]Vathiotis IA, et al. Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond. Cancers (Basel) . 2023 Feb 17;15 (4) :1286.|[3]Son J, et al. A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. Cancer Res. 2022 Apr 15;82 (8) :1633-1645.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1342897-01 0.02 mg (E-Coli)
Recombinant Pseudoalteromonas atlantica Succinylglutamate desuccinylase (astE)
Sign In for Pricing
View Details MBS1342897-02 0.02 mg (Yeast)
Recombinant Pseudoalteromonas atlantica Succinylglutamate desuccinylase (astE)
Sign In for Pricing
View Details